Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 02:30:00 13/12/2025 am IST			5-day change	1st Jan Change
40.88 ^USD	-1.23%		-7.84%	+22.76%

11/12	Exelixis, Inc. - Special Call
25/11	Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing	MT

Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12

Published on 09/03/2025 at 11:35 pm IST - Modified on 09/04/2025 at 12:50 am IST

S&P Capital IQ

Presenter Speech
Derek Archila (Analysts)

All right, everyone. I think we'll get started here with the first session after lunch time. But my name is Derek Archila. I'm one of the senior biotech

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Exelixis, Inc.

11/12	Exelixis, Inc. - Special Call
25/11	Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $4,355,000, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $2,056,278, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $1,032,414, According to a Recent SEC Filing	MT
11/11	Exelixis, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-10-2025 10:30 AM
08/11	Exelixis, Inc. Announces Executive Changes, Effective November 7, 2025	CI
06/11	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
05/11	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
05/11	Exelixis, Inc., Q3 2025 Earnings Call, Nov 04, 2025
05/11	Exelixis Inc authorizes $750 million stock repurchase by 2026 - SEC filing	RE
05/11	Exelixis Q3 Non-GAAP Earnings, Revenue Increase	MT
05/11	Exelixis Q3 revenue beats analyst expectations	RE
05/11	Earnings Flash (EXEL) Exelixis, Inc. Posts Q3 Adjusted EPS $0.78 per Share, vs. FactSet Est of $0.69	MT
05/11	Earnings Flash (EXEL) Exelixis, Inc. Reports Q3 Revenue $597.8M, vs. FactSet Est of $590.2M	MT
05/11	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.	CI
05/11	Exelixis, Inc. announces an Equity Buyback for $750 million worth of its shares.	CI
05/11	Exelixis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Exelixis, Inc. Updates Earnings Guidance for Fiscal Year 2025	CI
01/10	Exelixis, Inc. authorizes a Buyback Plan.	CI
04/11	Sector Update: Health Care Stocks Softer Late Afternoon	MT
04/11	Exelixis Shares Fall After Guggenheim Downgrade	MT
03/11	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
29/10	Merck-Eisai's kidney cancer drug combo meets one endpoint of late-stage study	RE
22/10	Exelixis Shares Rise After Leerink Partners Upgrade	MT